Puma 10-Q Discloses New Material Weakness Tied to ERP Rollout; Q3 Net Income Falls to $6.0M
PBYI sits 83% above its 52-week low of $4.575 on elevated volume (2.1× avg).
Summary
Puma's Q3 10-Q first discloses a material weakness in internal controls stemming from its new ERP system, alongside net income of $6.0M for the quarter (down from $8.8M) and $108.6M in cash and securities.
Key Events · Corporate Governance and Compliance · PBYI
-
New Material Weakness Disclosed
Management identified a material weakness in internal control over financial reporting during Q3 2026 tied to the January 1, 2026 ERP implementation — unsegregated privileged access and inconsistent access- and change-management monitoring — and concluded disclosure controls were not effective at September 30, 2026.
-
Weakness Also Existed at June 30
A retrospective review found the same material weakness existed as of June 30, 2026 but was not identified then; management says compensating procedures found no material misstatements and no restatement is required.
-
Q3 Net Income Falls to $6.0M
Third-quarter net income was $5.956M ($0.12 basic / $0.11 diluted) versus $8.844M a year ago; nine-month net income was $10.392M versus $17.673M, with R&D up to $18.283M from $15.912M on higher alisertib study activity.
-
China Royalty Rate Cut
A $2.1M reduction to royalty revenue was recorded as a change in accounting estimate after third-party data showed generic NERLYNX market share in China crossed the contractual threshold; a reduced royalty rate applies going forward.
Analysis · PBYI · Life Sciences
The headline numbers were already out on November 5, but this 10-Q carries the first disclosure of a material weakness in internal control over financial reporting, tied to the January 1, 2026 ERP implementation. Privileged access was granted without segregation of duties, and change-management controls were not consistently operating; management concluded disclosure controls were not effective at September 30, 2026. The weakness also existed at June 30, 2026 and was missed then, though management says no restatement is needed after a retrospective review. Against that, the business still generates cash — $31.6M from operations over nine months and $108.6M of cash plus securities — and the Athyrium debt is fully repaid, so the control problem is a governance and reporting-quality issue rather than a liquidity one.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBYI was trading at $8.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $433.4M. The 52-week trading range was $4.58 to $11.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.